MassBio Releases 2020 Massachusetts Biopharma Funding Report
MassBio’s latest Biopharma Funding Report shows Massachusetts biopharma companies raised record-breaking $5.8 billion in VC Funding in 2020.
MassBio today released its 2020 Massachusetts Biopharma Funding Report, which shows that the Massachusetts biopharma industry experienced its best funding year on record. In 2020, venture capital investment in Massachusetts biopharma companies reached $5.8 billion, surpassing 2018’s previous recorded high of $4.8 billion.
In addition, 21 Massachusetts biotech companies went public in 2020, a 110% increase from 2019, totaling $3.9 billion raised. These Massachusetts companies accounted for 32% of all United States-based biotech IPOs by volume. Additionally, two Massachusetts biotechs went public through a special purpose acquisition company (SPAC) merger in 2020, representing 50% of all United States-based biotech SPAC mergers in 2020.
The report also found that Cambridge, Massachusetts remains a driving force within the life sciences industry. Cambridge-based biopharma companies received 55% of all biotech VC investment in Massachusetts and raised 63% of all IPO money.
To download the full report, click here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
